America is facing a critical shortage of many medically important drugs. The good news? There's a simple solution if we're willing to implement it. The Biden Administration is poised to invest billions of dollars in America's "bioeconomy." Will this really boost the US biotech sector, or just waste valuable resources that should be spent elsewhere?
Join host Cameron English as he sits down Dr. Henry Miller to break down these stories on episode 34 of the Science Dispatch podcast:
Shortages of widely prescribed drugs are endemic in the U.S. To address the problem, we need a policy change that would enable overseas manufacturers to sell products in the U.S. that already have received marketing approval from certain foreign governments with standards comparable to ours and vice versa. In other words, there should be reciprocity of drug approvals.
The Biden Administration's attempt to boost the "bioeconomy" is burdened with bureaucratic requirements and busy-work initiatives and projects. It will fail.
Listen to the Science Dispatch on iTunes Spotify, Stitcher and Google Podcasts. Or add the RSS feed to your favorite podcast app. Join our Dispatch newsletter to get these stories and more delivered to your inbox.
